Using host response modifiers in the treatment of periodontal disease.
Periodontal disease is the result of a complex interaction between microbial plaque, the host's inflammatory response to the plaque, and host modifying factors (e.g., smoking, diabetes, genetics) that may have an impact on the disease process. It is known that plaque initiates periodontal disease but that the host response is responsible for the destruction of periodontal tissues. This article describes why host response modifiers may be used to help control inflammation and tissue destruction as part of the initial phase of periodontal therapy in selected patient groups.
Novak
M John
MJ
Center for Oral Health Research, University of Kentucky, Lexington.
Donley
Timothy G
TG
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003773:Dental Plaque / Q000150:complications / Q000382:microbiology / Q000517:prevention & control; D003777:Dental Prophylaxis; D048909:Diabetes Complications; D004318:Doxycycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000502:physiology; D007752:Obstetric Labor, Premature / Q000209:etiology; D010518:Periodontitis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D011247:Pregnancy; D011480:Protease Inhibitors / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007155:Immunologic Factors; D018836:Inflammation Mediators; D011480:Protease Inhibitors; D004318:Doxycycline